# Clene Inc.: overview CLNN · Nasdaq · CIK 1822791 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/clnn.md) · [Financials](/companies/clnn/financials.md) · [Filings](/companies/clnn/filings.md) · [Insiders](/companies/clnn/insiders.md) Latest reported revenue: [$90.0k](/filings/0001437749-26-027828.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001437749-26-027828). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [87.0](/filings/0001437749-25-034613.md) | [91.0 d](/filings/0001437749-26-008502.md) | [81.0](/filings/0001437749-26-016878.md) | [27.0](/filings/0001437749-26-027828.md) | [15.0](/filings/0001437749-25-034613.md) | [77.0 d](/filings/0001437749-26-008502.md) | [15.0](/filings/0001437749-26-016878.md) | [90.0](/filings/0001437749-26-027828.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(8982.8%)](/filings/0001437749-25-034613.md) | [(9511.0%) d](/filings/0001437749-26-008502.md) | [(5032.1%)](/filings/0001437749-26-016878.md) | [(21718.5%)](/filings/0001437749-26-027828.md) | [(37653.3%)](/filings/0001437749-25-034613.md) | [(9733.8%) d](/filings/0001437749-26-008502.md) | [(13740.0%)](/filings/0001437749-26-016878.md) | [(5941.1%)](/filings/0001437749-26-027828.md) | | Net margin | % | [(9179.3%)](/filings/0001437749-25-034613.md) | [(14889.0%) d](/filings/0001437749-26-008502.md) | [(927.2%)](/filings/0001437749-26-027828.md) | [(27477.8%)](/filings/0001437749-26-027828.md) | [(58513.3%)](/filings/0001437749-25-034613.md) | [(11981.8%) d](/filings/0001437749-26-008502.md) | [(53940.0%)](/filings/0001437749-26-027828.md) | [(14915.6%)](/filings/0001437749-26-027828.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $k | [(3,024) d](/filings/0001437749-25-034613.md) | [(4,866) d](/filings/0001437749-26-008502.md) | [(5,011)](/filings/0001437749-26-016878.md) | [(4,744) d](/filings/0001437749-26-027828.md) | [(4,003) d](/filings/0001437749-25-034613.md) | [(4,827) d](/filings/0001437749-26-008502.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.7](/filings/0001437749-23-006264.md) | [0.5](/filings/0001437749-24-007542.md) | [0.7](/filings/0001437749-25-008956.md) | [0.3](/filings/0001437749-26-008502.md) | [0.2](/filings/0001437749-26-008502.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(6912.6%)](/filings/0001437749-23-006264.md) | [(10234.5%)](/filings/0001437749-24-007542.md) | [(6198.8%)](/filings/0001437749-25-008956.md) | [(9676.3%)](/filings/0001437749-26-008502.md) | [(11541.5%)](/filings/0001437749-26-008502.md) | | Net margin | % | [(1347.2%)](/filings/0001437749-23-006264.md) | [(6325.2%)](/filings/0001437749-24-007542.md) | [(7569.4%)](/filings/0001437749-25-008956.md) | [(11520.5%)](/filings/0001437749-26-008502.md) | [(13086.5%)](/filings/0001437749-26-008502.md) | | Diluted EPS | $ per share | [(0.16)](/filings/0000950170-22-003410.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(36.0)](/filings/0001437749-23-006264.md) | [(44.2)](/filings/0001437749-24-007542.md) | [(30.5)](/filings/0001437749-25-008956.md) | [(21.3)](/filings/0001437749-26-008502.md) | [(18.6)](/filings/0001437749-26-008502.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/clnn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Empery Asset Management, LP](/funds/1469336.md) | 2026-06-30 | $5.6m | 916,532 | | New +916,532 | | [SCOGGIN MANAGEMENT LP](/funds/1086416.md) | 2026-06-30 | $3.7m | 600,000 | | Added +300,000 | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $2.9m | 477,515 | | Unchanged | | [Ensign Peak Advisors, Inc](/funds/1454984.md) | 2026-06-30 | $2.1m | 348,062 | | Added +90,190 | | [SymBiosis Capital Partners, LLC](/funds/2006045.md) | 2026-03-31 | $2.1m | 431,094 | | Not compared | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.1m | 333,706 | | Added +25,476 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $629.6k | 102,215 | | Added +6,341 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $378.9k | 61,559 | | Added +27,760 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $355.5k | 57,765 | | Added +14,050 | | [Lunt Capital Management, Inc.](/funds/1608034.md) | 2026-06-30 | $321.7k | 52,260 | | Unchanged | ## Recent filings [All 701 filings](/companies/clnn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 23:37 ET | [8-K](/filings/0001437749-26-032960.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-26-032960 | | 2026-10-19 | 12:05 ET | [8-K](/filings/0001437749-26-032882.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032882 | | 2026-09-16 | 21:13 ET | [8-K](/filings/0001437749-26-030581.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-030581 | | 2026-08-14 | 12:35 ET | [8-K](/filings/0001437749-26-027837.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027837 | | 2026-08-14 | 12:01 ET | [10-Q](/filings/0001437749-26-027828.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027828 | | 2026-08-10 | 12:07 ET | [8-K](/filings/0001437749-26-026653.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-026653 | | 2026-05-22 | 20:37 ET | [8-K](/filings/0001437749-26-018267.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-018267 | | 2026-05-14 | 12:02 ET | [8-K](/filings/0001437749-26-016881.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-016881 | | 2026-05-14 | 11:54 ET | [10-Q](/filings/0001437749-26-016878.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016878 | | 2026-05-05 | 21:06 ET | [8-K](/filings/0001437749-26-014946.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-014946 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-008502.md), filed Mar 17, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/39d0994c-9994-46b7-9e45-4d8b088e3871) ## About the filer - CIK: 1822791 - Tickers: CLNN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.